Patents by Inventor Nobuo Shimma
Nobuo Shimma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200270220Abstract: An object of the present invention is to provide a novel ascochlorin derivative which activates adenosine monophosphate-activated protein kinase (AMPK), and is useful in the treatment or prevention of diseases or conditions that involve AMPK dysregulation. The present invention provides a compound presented by formula I, a pharmaceutically acceptable salt or a solvate thereof.Type: ApplicationFiled: January 4, 2017Publication date: August 27, 2020Inventors: Nobuo SHIMMA, Tatsuo HOSHINO
-
Patent number: 8648054Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: GrantFiled: April 12, 2013Date of Patent: February 11, 2014Assignee: Roche Palo Alto LLCInventors: Rene Robert Devos, Christopher John Hobbs, Wen-Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Patent number: 8609656Abstract: The present invention provides a compound represented by the formula (1): wherein R1, R2 and R5 are each independently selected from a hydrogen atom, a halogen atom, a C1-C6 alkyl is substituted with a halogen atom and the like; R3 and R4 are each independently selected from a hydrogen atom, a halogen atom, a substituted C1-C6 alkyl group and the like; R6 and R7 are each independently selected from a hydrogen atom and a halogen atom; Z1 and Z2 are each independently selected from a hydrogen atom, a hydroxyl group and —O(CHR11)OC(?O)R12; Q is a group of the formula: (wherein G1 is C—Y2 or N; a ring A is a benzene ring or a 5- to 6-membered unsaturated heterocycle) a pharmaceutically acceptable salt thereof or a prodrug thereof.Type: GrantFiled: February 23, 2005Date of Patent: December 17, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Nobuhiro Oikawa, Eisaku Mizuguchi, Kenji Morikami, Nobuo Shimma, Nobuya Ishii, Toshiyuki Tsukaguchi, Sawako Ozawa
-
Patent number: 8575391Abstract: An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].Type: GrantFiled: April 1, 2010Date of Patent: November 5, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshiaki Isshiki, Yasunori Kohchi, Eisaku Mizuguchi, Hitoshi Iikura, Yasuaki Matsubara, Shinji Tsujii, Nobuo Shimma, Masanori Miwa, Satoshi Aida, Masami Kohchi, Takeshi Murata, Kosuke Aso
-
Publication number: 20130237491Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: April 12, 2013Publication date: September 12, 2013Applicant: Roche Palo Alto LLCInventors: Rene Robert Devos, Christopher John Hobbs, Wen-Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Patent number: 8362236Abstract: The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof: wherein X, R1, R2, R3, R4, R5, R6, R7, L1, L2, and L3 are as defined in the specification.Type: GrantFiled: February 29, 2008Date of Patent: January 29, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Nobuo Shimma, Takuo Tsukuda, Hiroshi Koyano, Atsushi Suda, Tadakatsu Hayase, Kihito Hada, Ken-Ichi Kawasaki, Susumu Komiyama, Naomi Ono, Toshikazu Yamazaki, Ryoichi Saitoh, Masami Kohchi, Kiyoshi Hasegawa
-
Patent number: 8299252Abstract: It is intended to provide a compound represented by the formula (1): [wherein Ar is an arylene group to be attached selected from the following formula (2): (wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents —(O)n—R; R represents a C1-C6 alkyl group or the like; n represents 0 or 1; X represents O or the like; R2, R3 and R4 are independently selected from a hydrogen atom or C1-C3 alkyl; or R2 and R3 may join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.Type: GrantFiled: August 4, 2006Date of Patent: October 30, 2012Assignees: Chugai Seiyaku Kabushiki Kaisha, The University of TokyoInventors: Sawako Ozawa, Nobuhiro Oikawa, Eisaku Mizuguchi, Hirosato Ebiike, Fumio Watanabe, Kenji Morikami, Nobuo Shimma, Nobuya Ishii, Toshiyuki Tsukaguchi
-
Publication number: 20120034184Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: October 17, 2011Publication date: February 9, 2012Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Patent number: 8084645Abstract: A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below: wherein, R1, R2, R3, R4, R5, R6, Q, R8, and R9 have the same meanings as R1, R2, R3, R4, R5, R6, Q, R8, and R9 in the specification.Type: GrantFiled: September 16, 2004Date of Patent: December 27, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshiaki Isshiki, Yasunori Kohchi, Kazuo Hattori, Nobuo Shimma, Masanori Miwa, Naohito Inagaki, Hitoshi Iikura, Yasuaki Matsubara
-
Patent number: 8071567Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: GrantFiled: September 16, 2009Date of Patent: December 6, 2011Assignee: Roche Palo Alto LLCInventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Patent number: 8048897Abstract: A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity.Type: GrantFiled: July 26, 2005Date of Patent: November 1, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroharu Matsuoka, Tsutomu Sato, Masahiro Nishimoto, Nobuo Shimma
-
Patent number: 8022205Abstract: A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represented by formula (I): [wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and R1 represents a cyclic substituent].Type: GrantFiled: August 7, 2007Date of Patent: September 20, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Nobuo Shimma, Hirosato Ebiike, Jun Ohwada, Hatsuo Kawada, Kenji Morikami, Mitsuaki Nakamura, Miyuki Yoshida, Nobuya Ishii, Masami Hasegawa, Shun Yamamoto, Kohei Koyama
-
Patent number: 7915232Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof which inhibit HCV polymerase and are useful for treating a patient suffering from a HCV infection and to pharmaceutical compositions containing such compounds.Type: GrantFiled: September 14, 2009Date of Patent: March 29, 2011Assignee: Roche Palo Alto LLCInventors: Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda
-
Publication number: 20100197676Abstract: An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].Type: ApplicationFiled: April 1, 2010Publication date: August 5, 2010Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yoshiaki Isshiki, Yasunori Kohchi, Eisaku Mizuguchi, Hitoshi Iikura, Yasuaki Matsubara, Shinji Tsujii, Nobuo Shimma, Masanori Miwa, Satoshi Aida, Masami Kohchi, Takeshi Murata, Kosuke Aso
-
Publication number: 20100168430Abstract: It is intended to provide a compound represented by the formula (1): [wherein Ar is an arylene group to be attached selected from the following formula (2): (wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents —(O)n—R; R represents a C1-C6 alkyl group or the like; n represents 0 or 1; X represents O or the like; R2, R3 and R4 are independently selected from a hydrogen atom or C1-C3 alkyl; or R2 and R3 may join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.Type: ApplicationFiled: August 4, 2006Publication date: July 1, 2010Applicants: Chugai Seiyaku Kabushiki Kaisha, The University of TokyoInventors: Sawako Ozawa, Nobuhiro Oikawa, Eisaku Mizuguchi, Hirosato Ebiike, Fumio Watanabe, Kenji Morikami, Nobuo Shimma, Nobuya Ishii, Toshiyuki Tsukaguchi, Yasuhiro Tamaki, Hidenori Takahashi
-
Patent number: 7745663Abstract: An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].Type: GrantFiled: July 26, 2005Date of Patent: June 29, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshiaki Isshiki, Yasunori Kohchi, Eisaku Mizuguchi, Hitoshi Iikura, Yasuaki Matsubara, Shinji Tsujii, Nobuo Shimma, Masanori Miwa, Satoshi Aida, Masami Kohchi, Takeshi Murata, Kosuke Aso
-
Publication number: 20100069629Abstract: A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represented by formula (I): [wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and R1 represents a cyclic substituent].Type: ApplicationFiled: August 7, 2007Publication date: March 18, 2010Inventors: Nobuo Shimma, Hirosato Ebiike, Jun Ohwada, Hatsuo Kawada, Kenji Morikami, Mitsuaki Nakamura, Miyuki Yoshida, Nobuya Ishii, Masami Hasegawa, Shun Yamamoto, Kohei Koyama
-
Publication number: 20100056510Abstract: The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof: wherein X, R1, R2, R3, R4, R5, R6, R7, L1, L2, and L3 are as defined in the specification.Type: ApplicationFiled: February 29, 2008Publication date: March 4, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Nobuo Shimma, Takuo Tsukuda, Hiroshi Koyano, Atsushi Suda, Tadakatsu Hayase, Kihito Hada, Ken-ichi Kawasaki, Susumu Komiyama, Naomi Ono, Toshikazu Yamazaki, Ryoichi Saitoh, Masami Kohchi, Kiyoshi Hasegawa
-
Publication number: 20100004192Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: September 14, 2009Publication date: January 7, 2010Inventors: Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda
-
Publication number: 20100003213Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: September 16, 2009Publication date: January 7, 2010Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda